Orchid Pharma faces liquidation as lenders reject resolution plan

MUMBAI: The lenders to Orchid Pharma have rejected the resolution plan of the bankrupt company, a decision that could push the troubled drug-maker toward liquidation. “The resolution professional has conducted three rounds of bidding.

However, lenders found bids in all the rounds unacceptable,” two senior persons who did not want to be named told ET late Monday. Time was running out for resolving this outstanding debt: The 270- day deadline before which a resolution has to be in place ended on May 14.

Orchid Pharma was referred to the bankruptcy court by Lakshmi Vilas Bank after it failed to pay about Rs 3,500 crore to lenders. It is also in the second list of 28 companies that the Reserve Bank of India had mandated banks to refer to the bankruptcy court by the end of December 2017 if lenders were unable restructure the respective loans by mid-December.

In the third round, the RP received four applications, of which three were legally compliant. At an e-voting held on May 12, the majority of the lenders rejected the offers they received and no resolution plan was put in place by May 14 – the last day of submitting a plan to the bankruptcy court. It is yet not clear whether the RP will seek additional time from the bankruptcy court to revive the company with a resolution plan.

Orchid Pharma has informed the stock exchange that as “the proposed resolution plan that was put for voting did not get requisite approval from the Committee of creditors (CoC), the CoC, through the RP has not submitted a resolution plan with Hon’ble National Company Law Tribunal.”

Union Quimico Farmacéutica, Ingen Capital and Fidelity Trading Corporation were the three bidders in the second round of auctions held in April but their bids were rejected since two of them – Ingen Capital and Fidelity Trading Corporation – were found to be ineligible as they were not compliant with Section 29A of the insolvency code. The offer from Union Quimico Farmacéutica was too low even though it was eligible.

As per the bankruptcy norms, Section 29A bars those companies that have defaulted on payments to lenders from bidding for other stressed assets.

Earlier in April, a bank official told ET that the bid of Union Quimico Farmacéutica was eligible but lenders found its offer of Rs 600 crore payable over a period of three to six years unacceptable.

  • Related Posts

    • Pharma
    • June 6, 2025
    • 204 views
    Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

    Mumbai-based pharma major Wockhardt, which is all set to launch its new class of antibiotic Zaynich targeted at treating complicated gram-negative infections in India this year, estimates that the drug…

    • Pharma
    • June 6, 2025
    • 136 views
    Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

    In a joint crackdown, Odisha’s Drugs Control administration and Crime Branch Special Task Force (STF) raided Unit-1 Market in Bhubaneswar on Thursday, seizing duplicate cosmetic products sold under top brand…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

    Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

    Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

    Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

    Illegally stocked drugs worth Rs 5.21 lakh seized

    Illegally stocked drugs worth Rs 5.21 lakh seized

    Patanjali and AIIMS Bhopal partner to develop holistic treatment solutions

    Patanjali and AIIMS Bhopal partner to develop holistic treatment solutions